Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P50135
UPID:
HNMT_HUMAN
Alternative names:
-
Alternative UPACC:
P50135; B2R9J3; Q546Z6; Q7Z7I2; Q8IU56; Q8WW98; Q9BRW6
Background:
Histamine N-methyltransferase, encoded by the gene with accession number P50135, plays a crucial role in the inactivation of histamine through N-methylation. This enzyme is pivotal in regulating histamine levels, thereby influencing the airway response to histamine and contributing to the degradation of this important mediator in allergic reactions.
Therapeutic significance:
The enzyme's association with Intellectual developmental disorder, autosomal recessive 51, underscores its genetic and clinical significance. Understanding the role of Histamine N-methyltransferase could open doors to potential therapeutic strategies for managing conditions related to histamine imbalance and intellectual developmental disorders.